BIDMC and Diagnostics For All create first low-cost, paper-based, point of care liver function test

September 19, 2012

A new postage stamp-sized, paper-based device could provide a simple and reliable way to monitor for liver damage at a cost of only pennies per test, say researchers at Beth Israel Deaconess Medical Center (BIDMC) and Diagnostics For All (DFA), a Cambridge, MA nonprofit dedicated to improving the health of people living in the developing world.

"Our device is designed to use a droplet of blood from a finger prick to deliver results in 15 minutes," says co-lead author Nira Pollock, MD, PhD, an infectious diseases doctor at BIDMC and the Associate Director of the Infectious Diseases Diagnostic Laboratory at Boston Children's Hospital. "It could have significant implications around the world, particularly in developing nations where blood tests can be prohibitively expensive and the results can sometimes take weeks to return."

A research article detailing the development of the device appears in the Sept. 19 issue of Science Translational Medicine.

In developed countries, blood tests to monitor are routine for patients with and those taking medications known to potentially cause . In the United States, it's standard practice to test levels of two that are important markers for monitoring damage to – aspartate aminotransferase (AST) and (ALT) – in at-risk patients on treatment for tuberculosis (TB) and HIV. In those patients, elevated AST and ALT levels can indicate drug-induced liver injury (DILI) and the potential need to change or stop important medications.

Two to 33 percent of patients on TB therapy can experience DILI, as can upwards of 13 percent of on certain medications, particularly nevirapine, which is widely used in the developing world.

The gold standard for measurement of these liver enzymes is to draw blood from a vein and send it to a lab where the serum or plasma is separated out and tested on a large automated platform. While this automated testing is excellent, it is impractical and too expensive in many parts of the developing world. Consequently, "in many resource-limited settings, patients with TB and/or HIV receive minimal or no monitoring during treatment," the authors write.

Hoping to address these obstacles, Pollock collaborated with Diagnostics For All to create the first paper-based microfluidic device that, for a few cents can be employed at the point of contact to test both AST and ALT levels concurrently, giving doctors near real time feedback and thus allowing them to make treatment plans, if necessary, on the spot.

The device – based in part on technology created in the lab of DFA founder and Harvard chemist George Whitesides, PhD – is constructed using layers of patterned paper and a plasma separation membrane. "A hole in the lamination allows for a fingerstick or pipetted drop of whole blood or serum to be applied to the plasma separation membrane." The blood then wicks into the layers of paper, and through the microfluidic channels travels to separate zones for testing AST and ALT.

"To imagine how it works, think of a paper litmus test," says co-lead author Jason Rolland, PhD, Senior Director of Research at DFA. "A drop of blood is applied to the device and the activity of the enzymes present in the blood sample leads to changes in levels of specific dyes present in the paper zones. This gives rise to color changes that can be compared against a visual read guide and correspond to a concentration range for each of the enzymes."

The color changes, for example, from shades of blue to shades of pink, when increasing levels of AST are detected in the blood. "We specifically optimized the interpretable ranges for AST and ALT values (color readouts in the test zone) to correspond to the cutoffs currently used for clinical management decisions per TB treatment guidelines in the United States," write the authors.

In rigorous clinical tests using 223 whole blood and serum specimens from BIDMC, Pollock and Rolland's paper-based test performed at greater than 90 percent accuracy compared against the gold standard automated platform test.

"Ultimately, this device could significantly impact patient care, particularly in resource-limited areas, and it could be also used to measure other types of , for example, that due to viral hepatitis," says Pollock. "This type of paper microfluidic platform is highly flexible so it can be used to construct a variety of other diagnostic assays as well," adds Rolland.

Diagnostics For All is currently developing a range of other tests for use in maternal and child health, infectious disease diagnosis and even agricultural tests, such as bovine (cow) pregnancy, for rural farmers in Africa.

Additionally, the device could be used as a "triage test" in developed or developing nations to quickly and inexpensively rule out the need for automated laboratory testing. For example, if blood tested with the device shows that the liver enzymes fall below a certain threshold, more expensive testing could be avoided, saving healthcare dollars and clinical resources.

"The next stage for the device is to test it in the field," says Pollock. "We are working with the global health nonprofit PATH in Seattle, WA for a preliminary field study of the paper-based test in Ho Chi Minh City, Vietnam. The field study is a collaboration with the BIDMC-based Harvard Medical School AIDS Initiative in Vietnam and the Hospital of Tropical Diseases in Ho Chi Minh City. We will evaluate the performance of the test for fingerstick testing of 600 patients from the Hospital of Tropical Diseases HIV clinic."

Explore further: Model predicts death due to acetaminophen overdose

Related Stories

Model predicts death due to acetaminophen overdose

February 24, 2012
(HealthDay) -- Model for Acetaminophen-induced Liver Damage (MALD), a mathematical model that utilizes commonly obtained laboratory values, including overdose amount and time elapsed since overdose, is effective for predicting ...

Innovative hand-held lab-on-a-chip could streamline blood testing

July 31, 2011
Samuel K. Sia, assistant professor of biomedical engineering at Columbia Engineering, has developed an innovative strategy for an integrated microfluidic-based diagnostic device—in effect, a lab-on-a-chip—that can ...

Abnormal liver tests associated with increased death rates in people over 75

August 2, 2011
One in six people over 75 are likely to have at least one abnormal liver test and those that have two or more are twice as likely to die from cancer and 17 times more likely to die from liver disease, according to research ...

Recommended for you

Exploring how herpes simplex virus changes when passed between family members

October 22, 2017
A new study explores how herpes simplex virus might change when passed from one individual to another, information that may prove useful in future development of therapeutics and vaccines. This rare glimpse into a transmission ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.